between People with Early Stage Breast Cancer and People Living with - - PowerPoint PPT Presentation

C a n a d i a n B r e a s t C a n c e r N e t w o r k

D i a n a E r m e l

DRUG ACCESS: How the Challenges Differ between People with Early Stage Breast Cancer and People Living with Metastatic Breast Cancer

Patient-Directed

We are the only national pa patient- dir directed breast cancer health charity. What does this mean? Our board of directors have all personally experienced a breast cancer diagnosis; we understand what the needs of patients and families are because we’ve been there.

DISCLOSURES

CBCN received unrestricted educational grants from: Full Circle Foundation for Wellness, Amgen, Astra Zeneca, Novartis, Pfizer, Roche, Healthy Cravings, & United Awareness Group for this project.

Aly ly Sc Schneid ider

Feb eb 28, , 1981 - Ja Jan 19, , 2017

• CBCN conducted a survey in 2017 of both early stage and

metastatic breast cancer patients to better understand the lived experience of both patient population; where similarities existed and where they differed.

• Results of this survey were published in the 2018 report

“Breast Cancer: The Lived Experience” which is available at www.CBCN.ca

• For the purpose of this survey Early Stage included Stage I, II

and III.

DATA SOURCE

KEY FINDINGS

1. The PATIENT EXPERIENCE varies significantly between patients with early stage breast cancer and those with metastatic breast cancer 2. PRIORITIES and PREFERENCES are also notably different between being treated in the curative setting vs. a non-curative setting. This presentation will focus on these experiences, priorities and preferences as they relate to DRUG ACCESS.

METASTATIC EARLY STAGE

PATIENT PROFILE

METASTATIC EARLY STAGE

PATIENT PROFILE

Provincial/territoria ial representation

Al Albe bert rta 6%, 6%, Br Brit itis ish Colum Columbia ia 8%, 8%, Manit Manitob

• ba

8%, 8%, Ne New Br Brun unswick 3%, 3%, Ne Newfoun undla land & Labr Labrado dor 5%, 5%, Nor Northwest Terr rrit itorie ries 1%, 1%, No Nova Sc Scot

• tia

ia 9%, 9%, Nuna Nunavut 0%, 0%, Ontar ario io 24 24%, Princ ince Edw dward Isl sland and 2%, 2%, Qué Québec 17 17%, Sas Saskatchewan 15 15% and and Yuk ukon 0. 0.41 41%

METASTATIC EARLY STAGE

DEMOGRAPHICS

Provinci cial/territoria ial representation

Alb Alberta 12 12%, , British sh Columbia 11 11%, , Mani anitoba 7% 7%, , New Brunswick 2% 2%, , Newfoundland & Lab Labrador 1%, , Nor

• rthwest Terr

erritories 0%, , Nova Sc Scotia 2% 2%, , Nunavut 0% 0%, , Ontario 40 40%, , Prince Edw dward Islan sland 2% 2%, , Qu Québec 15 15%, , Sas Saskatchewan 7% 7% and and Yukon 0% 0%

Level of

• f Education:

86 86% of

• f respo

spondents s had had po post-se secondary ry educ ducatio ion

Le Level of

• f Educatio

ion:

83 83% of f respondents ts ha have pos post-secondary educ ducatio ion

Ann Annual l Ho Hous usehol

• ld Inc

ncome:

30% 30% - $1 $100 00,000 or hi high gher 25% 25% - $6 $60,0 0,000 - $1 $100 00,000 19% 19% - unde under $6 $60,0 0,000

Ann Annual l Ho Hous usehol

• ld Inc

ncome:

26% 26% - $1 $100 00,000 or hi high gher 25% 25% - $6 $60,0 0,000 - $1 $100 00,000 21% 21% - und under $6 $60, 0,000

METASTATIC EARLY STAGE

PRIVATE INSURANCE

METASTATIC EARLY STAGE

COST OF CANCER TREATMENT TO PATIENTS

14% of people with early stage breast cancer were

prescribed cancer medications that were NO NOT covered through the public health care system.

1% of people with early stage breast cancer did

did NO NOT take a prescribed cancer medication due to cost.

39% of people with metastatic breast cancer were prescribed

cancer medications that were NO NOT covered through the public health care system.

8% of people with metastatic breast cancer did

did NO NOT take a prescribed cancer medication due to cost.

METASTATIC EARLY STAGE

COST OF SUPPORT MEDICATION TO PATIENTS

32% of people with early stage breast cancer were prescribed

suppo support rt medications that were no not covered through the public health care system.

2% of patients did

did no not take a support medication due to cost.

85% of people with metastatic breast cancer were prescribed

support medications that were no not covered through the public health care system.

7% of patients did

did no not take a support medication due to cost.

“I’m concerned with how long it takes to get a treatment approved and on the public health care lists and with the high cost of new treatments that have become available but are not yet covered under the public health care lists”

~Patient living with metastatic breast cancer

METASTATIC EARLY STAGE

HOW PATIENTS COVERED COSTS OF CANCER MEDICATIONS

METASTATIC EARLY STAGE

HOW PATIENTS COVERED COSTS OF SUPPORT MEDICATIONS

• Respondents living with metastatic breast cancer were

asked how much of an impact prescription medication costs had on their quality of life.

• Results show that over 50% of people living with

metastatic breast cancer had their quality of life impacted as a result of the cost of prescription medications.

IMPACT OF DRUG COSTS ON QUALITY OF LIFE

METASTATIC EARLY STAGE

FINANCIAL IMPACT

64% 64% exp xperie ience ced a a neg negative fin inanci cial impact ct 82% 82% exp xperie ience ced a a neg negative fin inanci cial impact ct

“I was in financial hardship and had to contact my credit card companies and speak to them about payment because we went from two incomes to one.”

~Patient with early stage breast cancer

“When medications aren’t covered, it is a tremendous financial burden, especially when I wasn’t working.”

~Patient living with metastatic breast cancer

“If you do not have private insurance, or are out of pocket until someone can help you, I’m not sure how people get through it.”

~Patient with early stage breast cancer

• Peo

eople liv ivin ing wit ith metastatic ic br breast cancer ar are e 3 3 tim imes s mor

• re lik

ikely than ear early ly stage pa patie ients to to be be pr prescrib ibed cancer treatments that ar are no not t pu publi licly ly fu funded. . This s is s a a barr barrier that acc accounts for

• r 8%

8% of

• f peo

people living wit ith metastatic br breast t cancer r no not t takin ing the cancer treatment rec ecommended by y their ph physic icia ian.

• There is

s an an increase sed ch chall llenge for

• r al

all l br breast cancer pa patie ients to to ac access s sup support med edications through th the pu public hea health car are system.

• It

It is s important to to rec ecognize the cr crit itical role

• le pl

played by pr priv ivate insurance an and man anufacturer pa patient assis assistance pr programs in n faci acilitatin ing affordable le ac access to to cancer med edications an and sup support med edicatio ions, , part particularly in the metastatic se setting.

• Dru

Drug cos

• sts

s neg negatively ly impact the qu qualit ity of

• f lif

ife of

• f over ha

half lf

• f
• f peo

people le liv iving with th metastatic br breast cancer. .

• A br

breast t cancer dia diagnosis s neg negatively ly impacts the fi finances

• f
• f bo

both th the ear early ly stage an and metastatic pa patient populations; having to pay for drugs that aren’t publicly covered fu further exacerbates th this is impact.

KEY TAKE-AWAYS

20

RECOMMENDATIONS

• Cancer medications be covered through public health

systems, particularly for metastatic breast cancer patients who experience the largest gap in public coverage.

• New breast cancer therapies be added to public

formularies in a timely manner to allow for patient access to innovative, life saving or extending treatments and not creating barriers to new therapies which are especially critical to the metastatic population

• Support medications be accessible to all cancer

patients to ensure optimal quality of life and minimize the risk of adverse events.

T H A N K Y O U

w w w . c b c n . c a

Diana Ermel +1 (613) -230-3044 Cbcn @cbcn.ca